Directory → Intermedianta → Serotoninergicakie funds → Imigran
This page is translated automatically with a help of Google Translate

Imigran

See also Sumatriptan

Roman name

Imigran

Characteristics

Selective agonist 5-ht_1-retseptorov (5-HT_1D).

Pharmacokinetics

Sumatriptan is rapidly absorbed after administration inwards and after intranasal. The ingestion 70% of the C_max plasma is the 45 minutes when administered in the dose of 100 mg C_max plasma averaged 54 ng / J Following intranasal S_max plasma achieved through 1-1.5 hrs at 12.9 ng / Ml.srednaa value absolute bioavailability when administered at 14% as a result of presistemnogo metabolism and incomplete removals. Because presistemnogo metabolism average absolute bioavailability in intra application is 15.8% of the one in the p / to the introduction. In patients with impaired liver would expect an increased level of sumatriptan plasma as a result of a decrease in presistemnogo Klirensa.stepen associate with the plasma protein small (14-21%), total distribution averages 170 litres T_1/2 approximately 2 hours Total plasma klirens averaged 1,160 mL / min and kidney klirens-260 ml / min, vnepochechny klirens about 80% of the total Klirensa.u adolescents (12-17 years) average C_max plasma was 13.9 ng / ml, the average T_1/2 about 2 hours Teenagers with excess weight is an insufficient and the distribution of products, so if you lower body weight they have greater exposure суматриптана.Основны�� a breeding sumatriptan is the way metabolism, which is being carried out by the action of the enzyme MAO type A main metabolite - indoluksousny analogue sumatriptan, appears mostly in the urine, where it is in the form of the free acid and glukuronidnyi kongugata. This metabolite has no activity against 5-HA_1- or 5-ht_2-retseptoram. Secondary metabolites have not been identified. Asthma migraines, do not appear to have had a significant impact on farmakokinetiku sumatriptan taken inside or route.

Farmakodinamika

The animals sumatriptan selectively big vessels in the sleepy streets, but does not alter cerebral blood. It is believed that the expansion of the blood vessels and / or swelling of the wall is the main mechanism of migraines in humans. The experimentally found that sumatriptan ingibiruet activity troinicnogo nerve. Both of these effects can be the basis protivomigrenoznogo of sumatriptan.

Clinical pharmacology

Clinical effects of the 30 minutes after administered orally at the dose of 100 mg and 15 minutes after intranasal.

Indications

Severe migraine attack (from skiing or without).

Pregnancy and lactation

No data on the high frequency of birth defects in the application of sumatriptan during pregnancy compared with the total population. However, pregnant women Imigran can be granted only if the projected benefits for a mother than the potential risk to the fetus. Avoid breast-feeding within 24 hours after sumatriptan.

Contraindications

Hypersensitivity; Gemiplegical, baziliarnaya and ofthalmoplegical of migraines; Myocardial infarction (incl. history); IBS or suspicion of its existence; Drinking Prinzmetala; Of peripheral vessels; Passing the cerebral circulation (including in history); Stroke (including in history); Uncontrolled arterial hypertension; Expressed by the liver and / or kidney; admission Imigrana with ergotaminom or its derivatives (including metisergid), as well as the admission of MAO inhibitors and up to two weeks after their Otmena.s caution : epilepsy (including any of the declining threshold sudorojna preparedness), arterial hypertension (controlled), pregnancy, lactation period, age up to 12 years old (safety and efficacy has not been established), age over 65 years.

Patient interaction

There has been interaction with sumatriptan propranololom, flunarizinom, pizotifenom and ethyl alcohol. Together with the admission ergotaminom been long suffering receptacles (sumatriptan could appoint not earlier than 24 hours after taking the drugs containing ergotamine, and preparations containing ergotamine, could be appointed not earlier than 6900 after taking sumatriptan). The interaction between sumatriptanom and MAO inhibitors, counter their simultaneous use. Very rarely can see the interaction between sumatriptanom and drugs from the group of selective inhibitors of reverse takeover serotonin (SIOSS).

Precautions

Imigran could not be applied as a preventive measure. The agent should be appointed only if the diagnosis is unquestionable. As in other protivomigrenozhnykh means in the appointment Imigrana in patients with previously illness migraine, or in patients with severe migraine to exclude other potentially serious neurological condition. It should be borne in mind that in patients with migraine increased risk of a cerebrovascular disorders (such as stroke or transient violation think кровообращения).Сумат риптан should not appoint patients with suspected heart disease without the prior survey with a view to eliminating the cardiovascular pathology. Such patients include women in post-menopausal stages, men over the age of 40 years and patients with risk factors for the development of ischemic heart disease. Although the survey does not always provide heart disease in some patients, it is very rare that they have side-effects of the cardiovascular system. After receiving sumatriptan may arise simply intense pain and tightness in the chest, extending to the neck area. If there is reason to believe that these symptoms are a manifestation of ischemic heart disease, it is necessary to hold a diagnostic обследование.Пациент��м controlled arterial hypertension sumatriptan should be appointed with caution because in a few cases there tranzithornoe the AD and peripheral vascular сопротивления.Имеютс�� sporadic reports of the weakness giperreflexii violation and coordination in patients after administration of sumatriptan and drugs from the group SIOSS, in the case of simultaneous appointments should be carefully monitored state Patienta.sleduet with caution sumatriptan use in patients suffering from such diseases, which are likely to be changed substantially induction, metabolism, or the withdrawal of the drug (such as the kidney or liver). There is a need to proceed with caution in patients with the disease in the epilepsy or structural brain damage, which will lower the threshold sudorojna Gotovnosti.u patients гиперчувствительност ью sulfanilamidam to introduce sumatriptan can cause allergic reactions that range from skin manifestations and arginine. The cross-sensitivity is limited, but should be careful in appointing such sumatriptan пациентам.Клинически�� experience with Imigrana in patients older (over 65) is limited. No significant differences in performance farmakokineticeskih sumatriptan the elderly and young patients, but until more data clinical research are encouraged to nominate Imigran patients over 65 Let.u patients with migraine may be sleepiness associated with the disease as well as hosting Imigrana, therefore, they should be particularly careful when driving and working with moving Mehanizmami.nelia exceed the recommended dose Imigrana.

Storage conditions

List B. At temperatures below 30 ° C

Shelf life

3 years

The registration

015723/01

All products of this group